US 11,813,278 B2
Highly active compounds against COVID-19
Jean-Pierre Sommadossi, Boston, MA (US); and Adel Moussa, Burlington, MA (US)
Assigned to Atea Pharmaceuticals, Inc., Boston, MA (US)
Filed by Atea Pharmaceuticals, Inc., Boston, MA (US)
Filed on Feb. 24, 2021, as Appl. No. 17/184,445.
Claims priority of provisional application 63/146,456, filed on Feb. 5, 2021.
Claims priority of provisional application 63/073,328, filed on Sep. 1, 2020.
Claims priority of provisional application 63/054,680, filed on Jul. 21, 2020.
Claims priority of provisional application 63/040,985, filed on Jun. 18, 2020.
Claims priority of provisional application 63/039,352, filed on Jun. 15, 2020.
Claims priority of provisional application 63/032,247, filed on May 29, 2020.
Claims priority of provisional application 62/994,206, filed on Mar. 24, 2020.
Claims priority of provisional application 62/982,670, filed on Feb. 27, 2020.
Prior Publication US 2022/0347199 A1, Nov. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7076 (2006.01); A61P 31/14 (2006.01); A61K 31/706 (2006.01); A61K 31/7064 (2006.01); A61K 9/08 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01)
CPC A61K 31/7076 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/08 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2054 (2013.01); A61K 31/706 (2013.01); A61K 31/7064 (2013.01); A61P 31/14 (2018.01)] 37 Claims
 
1. A method for the treatment of COVID-19 caused by the SARS-CoV-2 virus in a human host in need thereof comprising administering an effective amount of a compound of Formula I:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, wherein:
R1 is methyl;
R2 is aryl, or aryl(C1-C4alkyl);
R3 is hydrogen or C1-6alkyl;
R4a and R4b are independently selected from hydrogen, C1-6alkyl, and C3-7cycloalkyl; and
R5 is C1-6alkyl, C1-6haloalkyl, C3-7cycloalkyl, aryl(C1-C4alkyl)-, aryl, heteroaryl, or heteroalkyl.